Retrospective Analysis of Rechallenge with Ipilimumab in Patients with Metastatic Melanoma

<table class="table-group" id="tab1"><tr><td><table class="table"><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr class="thead"><td class="align_left">Primary site of melanoma</td><td class="align_center">Number of cases (%)</td></tr><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr><td class="align_left">Cutaneous</td><td class="align_center">10 (45)</td></tr><tr><td class="align_left">Acral</td><td class="align_center">6 (27)</td></tr><tr><td class="align_left">Choroidal</td><td class="align_center">2 (9)</td></tr><tr><td class="align_left">Mucosal</td><td class="align_center">2 (9)</td></tr><tr><td class="align_left">Unknown</td><td class="align_center">2 (9)</td></tr><tr class="table-tr"><td colspan="2"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

Journal of Skin Cancer

tab1

Table 1

Table 1: Retrospective Analysis of Rechallenge with Ipilimumab in Patients with Metastatic Melanoma 